Chris Kell

648 total citations · 1 hit paper
9 papers, 447 citations indexed

About

Chris Kell is a scholar working on Physiology, Immunology and Surgery. According to data from OpenAlex, Chris Kell has authored 9 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Physiology, 5 papers in Immunology and 4 papers in Surgery. Recurrent topics in Chris Kell's work include Asthma and respiratory diseases (6 papers), IL-33, ST2, and ILC Pathways (5 papers) and Eosinophilic Esophagitis (4 papers). Chris Kell is often cited by papers focused on Asthma and respiratory diseases (6 papers), IL-33, ST2, and ILC Pathways (5 papers) and Eosinophilic Esophagitis (4 papers). Chris Kell collaborates with scholars based in United Kingdom, Singapore and Spain. Chris Kell's co-authors include Dewei She, Christopher E. Brightling, Edward Piper, Gregory P. Geba, Robert Niven, Chad K. Oh, Raffaella Faggioni, Richard May, Néstor A. Molfino and Ian Glaspole and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal and British Journal of Clinical Pharmacology.

In The Last Decade

Chris Kell

9 papers receiving 430 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4

2025 19 citations Dave Singh, Sarah Doffman et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Kell United Kingdom	5	306	245	163	95	55	9	447
Yohei Yatagai Japan	11	183 0.6×	212 0.9×	71 0.4×	35 0.4×	41 0.7×	27	354
Hirohita Kita United States	4	444 1.5×	168 0.7×	209 1.3×	210 2.2×	116 2.1×	8	531
Chynna Huang Canada	8	399 1.3×	155 0.6×	370 2.3×	68 0.7×	267 4.9×	21	576
Anita Trikha United States	5	152 0.5×	78 0.3×	67 0.4×	60 0.6×	74 1.3×	8	232
Emanuele Vivarelli Italy	11	145 0.5×	130 0.5×	70 0.4×	66 0.7×	51 0.9×	33	336
Kit Wong United States	6	441 1.4×	126 0.5×	103 0.6×	472 5.0×	163 3.0×	9	716
Jane Gilbert United Kingdom	6	322 1.1×	99 0.4×	68 0.4×	261 2.7×	137 2.5×	9	501
Zhi Bin Lin China	11	145 0.5×	49 0.2×	50 0.3×	134 1.4×	103 1.9×	17	324
Regina T. Chustz United States	6	171 0.6×	35 0.1×	166 1.0×	147 1.5×	60 1.1×	8	398
Claus Bachert Germany	6	194 0.6×	80 0.3×	85 0.5×	149 1.6×	105 1.9×	14	349

Countries citing papers authored by Chris Kell

Since Specialization

Citations

This map shows the geographic impact of Chris Kell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Kell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Kell more than expected).

Fields of papers citing papers by Chris Kell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Kell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Kell. The network helps show where Chris Kell may publish in the future.

Co-authorship network of co-authors of Chris Kell

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Kell. A scholar is included among the top collaborators of Chris Kell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Kell. Chris Kell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Corren, Jonathan, Rachel Moate, Adam Williams, et al.. (2025). FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma. ERJ Open Research. 12(1). 183–2025. 1 indexed citations

2.

Singh, Dave, Sarah Doffman, Ulla Seppälä, et al.. (2025). A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. European Respiratory Journal. 66(1). 2402231–2402231. 19 indexed citations breakdown →

3.

Li, Yunfei, Hua Zhang, Hitesh Pandya, et al.. (2024). A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants. Clinical Pharmacology in Drug Development. 13(6). 665–671. 1 indexed citations

4.

Sadiq, Muhammad Waqas, Magnus Åstrand, Ian C. Scott, et al.. (2024). Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology. 90(12). 3286–3295. 2 indexed citations

5.

Pandya, Hitesh, Sarah Doffman, Lars H. Nordenmark, et al.. (2024). Late Breaking Abstract - FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD. OA1964–OA1964. 1 indexed citations

6.

Parker, Joseph M., Ian Glaspole, Lisa Lancaster, et al.. (2017). A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 197(1). 94–103. 90 indexed citations

7.

Sheldon, Eric, Martin Schwickart, Jing Li, et al.. (2016). Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study. Advances in Therapy. 33(2). 225–251. 36 indexed citations

8.

Piper, Edward, Christopher E. Brightling, Robert Niven, et al.. (2012). A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. European Respiratory Journal. 41(2). 330–338. 290 indexed citations

9.

Piper, Edward, Christopher E. Brightling, Robert Niven, et al.. (2011). Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma. European Respiratory Journal. 38(Suppl 55). 3425–3425. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact